31/08/2022 Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer
The Ministry of Health’s Drug Advisory Committee has recommended:
for treating metastatic mesenchymal epithelial transition exon 14 skipping (METex14sk) mutation-positive non-small-cell lung cancer (NSCLC) in line with specific clinical criteria.
Funding status
RTepotinib 225 mg tablet is recommended for inclusion on the MOH Cancer Drug List (CDL; MAF with MediShield Life monthly claim limit of $1,600) for the abovementioned indication from 1 September 2022.
NRCDL listing does not apply to any formulations or strengths of capmatinib for treating metastatic METex14sk mutation-positive NSCLC.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.